AstraZeneca Offloads More Mature Drugs To Focus On Core Activities
This article was originally published in Scrip
Executive Summary
China Medical System has agreed to pay a total of $500m for selected rights to two mature AstraZeneca PLC cardiovascular products, with the divestments set to provide new growth prospects for the Chinese firm while helping the UK-based multinational focus on innovative products in its second-largest global market.